Biospecifics Technologies (BSTC) Tops Q2 EPS by 2c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Biospecifics Technologies (NASDAQ: BSTC) reported Q2 EPS of $0.37, $0.02 better than the analyst estimate of $0.35. Revenue for the quarter came in at $6.2 million versus the consensus estimate of $6.25 million.
For earnings history and earnings-related data on Biospecifics Technologies (BSTC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agree Realty (ADC) Tops Q3 FFO by 4c
- Buckeye Partners (BPL) Tops Q3 EPS by 22c
- UPDATE: Corelogic (CLGX) Tops Q3 EPS by 7c, Expects to Achieve Upper Ends of FY16 Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!